Subasree Srinivasan
About
In The Last Decade
Subasree Srinivasan
18 papers receiving 406 citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Molecular Medicine 174
- Epidemiology 150
- Pharmacology 110
- Immunology 82
- Hepatology 81
Countries citing papers authored by Subasree Srinivasan
This map shows the geographic impact of Subasree Srinivasan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Subasree Srinivasan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Subasree Srinivasan more than expected).
Fields of papers citing papers by Subasree Srinivasan
This network shows the impact of papers produced by Subasree Srinivasan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Subasree Srinivasan. The network helps show where Subasree Srinivasan may publish in the future.
Co-authorship network of co-authors of Subasree Srinivasan
This figure shows the co-authorship network connecting the top 25 collaborators of Subasree Srinivasan. A scholar is included among the top collaborators of Subasree Srinivasan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Subasree Srinivasan. Subasree Srinivasan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) breakdown → | 146 |
| 4 | 1 | |
| 5 | 51 | |
| 6 | 13 | |
| 7 | 6 | |
| 8 | 1 | |
| 9 | 10 | |
| 10 | 9 | |
| 11 | 5 | |
| 12 | 28 | |
| 13 | 17 | |
| 14 | 3 | |
| 15 | 64 | |
| 16 | 18 | |
| 17 | 32 | |
| 18 | Formulation and Evaluation of Clarithromycin Extended Release Tablets | 3 |
| 19 | Antibodies to Cag A protein are not predictive of serious gastroduodenal disease in Indian patients. | 13 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.